In addition, previous studies demonstrated that patients exhibiting PRDX2 positive had a better prognosis than their PRDX2 negative counterparts in renal cell carcinomas [53] and astrocytic brain tumors [54]. Here, PRDX2 is linked to renal cell carcinoma.